

	Friday, September 3, 2010		Saturday, September 4, 2010		Sunday, September 5, 2010			
	Hall A	Hall B	Hall A	Hall B	Hall A	Hall B		
8:30-10:00	<b>Plenary Session 1</b>  <b>8:30-8:40</b> Opening Remarks  <b>8:40-9:20</b> Did we substantially improve MDS therapy in the last decade? <b>8:40-8:45</b> Moderator: E. Rachmilewitz <b>8:45-8:55</b> Yes: H. Kantarjian <b>8:55-9:05</b> No: C. Schiffer <b>9:05-9:20</b> Discussion  <b>9:20-10:00</b> Is there a role for SCT in Multiple Myeloma? <b>9:20-9:25</b> Moderator: J.F. San-Miguel <b>9:25-9:35</b> Yes: B. Barlogie <b>9:35-9:45</b> No: M. Boccadoro <b>9:45-10:00</b> Discussion		<b>Session 8</b> <b>STEM CELL TRANSPLANTATION (SCT) I</b> The role of Allogeneic SCT (AlloSCT) in Hematological Malignancies  <b>8:30-9:15</b> How should we treat a 60 year old patient with Myelodysplastic syndrome? <b>8:30-8:35</b> Moderator: M. Martelli <b>8:35-8:45</b> AlloSCT: N. Kröger <b>8:45-8:55</b> Conventional Therapy: U. Platzbecker <b>8:55-9:15</b> Discussion  Should all adult ALL patients have a stem cell transplantation in first remission or only high risk patients? <b>9:15-9:20</b> Moderator: W. Arcese <b>9:20-9:30</b> All: A. Goldstone <b>9:30-9:40</b> Only high risk: D. Hoelzer <b>9:40-10:00</b> Discussion		<b>Session 12</b> <b>COAGULATION</b>  <b>8:30-9:15</b> Are there indications for thrombolytic cancer patients during and after chemotherapy? <b>8:30-8:35</b> Moderator: M.M. Samama <b>8:35-8:45</b> Yes: A. Falanga <b>8:45-8:55</b> No: A. Kakkak <b>8:55-9:15</b> Discussion  <b>9:15-10:00</b> Is there still a role for splenectomy in ITP? <b>9:15-9:20</b> Moderator: A. Falanga <b>9:20-9:30</b> Yes: B. Godeau <b>9:30-9:40</b> No: J. Bussel <b>9:40-10:00</b> Discussion		<b>Session 16</b> <b>Myelo Proliferative Neoplasms (MPNs)</b>  <b>8:30-9:15</b> Are JAK2 positive PV, ET and IM different diseases? <b>8:30-8:35</b> Moderator: A. Tefferi <b>8:35-8:45</b> Yes: W. Vainchenker <b>8:45-8:55</b> No: A.M. Vannucchi <b>8:55-9:15</b> Discussion  <b>9:15-10:00</b> Do JAK2 inhibitors represent a major advance in the treatment of myeloproliferative neoplasms? <b>9:15-9:20</b> Moderator: W. Vainchenker <b>9:20-9:30</b> Yes: A. Tefferi <b>9:30-9:40</b> No: T. Barbui <b>9:40-10:00</b> Discussion	<b>Session 17</b> <b>INFECTIONS</b>  <b>8:30-9:15</b> Is there a role for empirical or pre-emptive antifungal treatment in patients with hematological malignancies? <b>8:30-8:35</b> Moderator: F. Menichetti <b>8:35-8:45</b> Yes: B. de Pauw <b>8:45-8:55</b> No: A. Prentice <b>8:55-9:15</b> Discussion  <b>9:15-10:00</b> Is monitoring of azole concentrations of clinical value in pts with hematological malignancies? <b>9:15-9:20</b> Moderator: B. de Pauw <b>9:20-9:30</b> Yes: F. Menichetti <b>9:30-9:40</b> No: P. Donnelly <b>9:40-10:00</b> Discussion
10:00-10:30	<i>Coffee Break</i>							
10:30-12:30	<b>Session 2</b> <b>ACUTE MYELOID LEUKEMIA (AML) I</b>  <b>10:30-11:30</b> About targeted therapies in AML: Have standard treatments reached their limits? <b>10:30-10:35</b> Moderator: S. Amadori <b>10:35-10:50</b> Yes: A. Burnett <b>10:50-11:05</b> No: B. Löwenberg <b>11:05-11:30</b> Discussion  <b>11:30-12:30</b> Should the therapy of AML be driven by MRD quantification? <b>11:30-11:35</b> Moderator: B. Löwenberg <b>11:35-11:50</b> Yes: S. Amadori <b>11:50-12:05</b> No: C. Schiffer <b>12:05-12:30</b> Discussion	<b>Session 5</b> <b>CHRONIC LYMPHATIC LEUKEMIA (CLL)</b>  <b>10:30-11:30</b> Is eradication of MRD feasible and worthwhile in CLL? <b>10:30-10:35</b> Moderator: K. Rai <b>10:35-10:50</b> Yes: G. Marti <b>10:50-11:05</b> No: G. Gaidano <b>11:05-11:30</b> Discussion  <b>11:30-12:30</b> Is the "wait and watch" philosophy still practical in the treatment of CLL even in younger patients? <b>11:30-11:35</b> Moderator: A. Polliack <b>11:35-11:50</b> Yes: K. Rai <b>11:50-12:05</b> No: F. Caligaris-Cappio <b>12:05-12:30</b> Discussion	<b>Session 9</b> <b>STEM CELL TRANSPLANTATION (SCT) II</b> Alternative Donor and Reduced Intensity Conditioning (RIC) AlloSCT  <b>10:30-11:40</b> Should CBT, Haploidentical transplant or MUD transplant be considered upfront if no sibling donor is available? <b>10:30-10:35</b> Moderator: A. Rambaldi <b>10:35-10:50</b> CBT: W. Arcese <b>10:50-11:05</b> Haplo: M. Martelli <b>11:05-11:20</b> MUD: A. Bacigalupo <b>11:20-11:40</b> Discussion  <b>11:40-12:30</b> Should we use AlloSCT in Acute Myeloid Leukemia RIC or Myeloablative preparative protocols? <b>11:40-11:45</b> Moderator: A. Bacigalupo <b>11:45-12:00</b> RIC: A. Nagler <b>12:00-12:15</b> Myeloablative: A. Rambaldi <b>12:15-12:30</b> Discussion	<b>Session 13</b> <b>CHRONIC MYELOID LEUKEMIA (CML) I</b> Is mutation analysis of BCR ABL of any value in clinical management of CML patients? <b>10:30-10:35</b> Moderator: J. Goldman <b>10:35-10:45</b> Yes: A. Hochhaus <b>10:45-10:55</b> No: D. Marin <b>10:55-11:10</b> Discussion  <b>11:10-11:50</b> Should first line imatinib treatment be optimized by combination with IFN or by higher imatinib dose? <b>11:10-11:15</b> Moderator: A. Hochhaus <b>11:15-11:25</b> Combination with IFN: F. Guilhot <b>11:25-11:35</b> Higher initial imatinib dose: R. Hehlmann <b>11:35-11:50</b> Discussion  <b>11:50-12:30</b> On the road to cure CML, does it matter to hit different pathways? <b>11:50-11:55</b> Moderator: R. Hehlmann <b>11:55-12:05</b> Yes: N. Shah <b>12:05-12:15</b> No: F. Giles <b>12:15-12:30</b> Discussion	<b>Plenary Session 18</b>  <b>10:30-11:05</b> Is there a role of biologic prognostic markers in the treatment of CLL? <b>10:30-10:35</b> Moderator: E. Rachmilewitz <b>10:35-10:45</b> For: R. Foà <b>10:45-11:05</b> Against: K. Rai <b>11:05-11:30</b> Discussion  <b>11:05-11:40</b> Are there sufficient indications for switching to new anticoagulant agents? <b>11:05-11:10</b> Moderator: G. Saglio <b>11:10-11:20</b> For: M.M. Samama <b>11:20-11:30</b> Against: A. Falanga <b>11:30-11:40</b> Discussion  <b>11:40-12:15</b> Which is the best chemotherapy regimen in Hodgkin Lymphoma? <b>11:40-11:45</b> Moderator: D. Straus <b>11:45-11:55</b> ABVD: A. Levis <b>11:55-12:05</b> BEACOPP: V. Diehl <b>12:05-12:15</b> Discussion  <b>12:15-12:30</b> Is chemotherapy alone sufficient for the treatment of Hodgkin Lymphoma? <b>12:15-12:30</b> Lecture: D. Straus			
12:30-13:15	<i>Lunch Break</i>							
13:15-14:30	<i>Novartis Satellite Symposium</i>		<i>Bristol-Myers Squibb / Otsuka Satellite Symposium</i>					
14:30-16:00	<b>Session 3</b> <b>ACUTE MYELOID LEUKEMIA (AML) II and ACUTE PROMYELOCYTIC LEUKEMIA (APL)</b>  <b>14:30-15:15</b> Do we require chemotherapy to cure APL? <b>14:30-14:35</b> Moderator: A. Burnett <b>14:35-14:45</b> Yes: M.A. Sanz <b>14:45-14:55</b> No: F. Lo-Coco <b>14:55-15:15</b> Discussion  <b>15:15-16:00</b> Can novel prognostic markers predict for success and guide therapy in AML? <b>15:15-15:20</b> Moderator: C. Schiffer <b>15:20-15:30</b> Yes: D. Grimwade <b>15:30-15:40</b> No: A. Burnett <b>15:40-16:00</b> Discussion	<b>Session 6</b> <b>INDOLENT NON-HODGKIN LYMPHOMA (NHL)</b>  <b>14:30-15:15</b> Is there a role for Rituximab in maintenance treatment in non-follicular indolent lymphomas? <b>14:30-14:35</b> Moderator: C. Portlock <b>14:35-14:45</b> Yes: A. Hagenbeek <b>14:45-14:55</b> No: C. Buske <b>14:55-15:15</b> Discussion  <b>15:15-16:00</b> Is molecular remission the goal in first line therapy of all patients with indolent non-Hodgkin lymphoma? <b>15:15-15:20</b> Moderator: A. Hagenbeek <b>15:20-15:30</b> Yes: P. Corradini <b>15:30-15:40</b> No: C. Tarella <b>15:40-16:00</b> Discussion	<b>Session 10</b> <b>MDS</b>  <b>14:30-15:15</b> Do hypomethylating agents improve survival in patients with high risk myelodysplastic syndromes? <b>14:30-14:35</b> Moderator: G. Leone <b>14:35-14:45</b> Yes: V. Santini <b>14:45-14:55</b> No: M. Cazzola <b>14:55-15:15</b> Discussion  <b>15:15-16:00</b> Is there a rationale for iron chelation therapy in MDS? <b>15:15-15:20</b> Moderator: E. Rachmilewitz <b>15:20-15:30</b> Yes: N. Gattermann <b>15:30-15:40</b> No: A. Tefferi <b>15:40-16:00</b> Discussion	<b>Session 14</b> <b>CHRONIC MYELOID LEUKEMIA (CML) II</b>  <b>14:30-15:15</b> Will second generation TKIs substitute imatinib as first line treatment of CML? <b>14:30-14:35</b> Moderator: R. Hehlmann <b>14:35-14:45</b> Yes: M. Baccarani <b>14:45-14:55</b> No: H. Kantarjian <b>14:55-15:15</b> Discussion  <b>15:15-16:00</b> Can we eventually stop TKI in all CML patients? <b>15:15-15:20</b> Moderator: M. Baccarani <b>15:20-15:30</b> Yes: F. Mahon <b>15:30-15:40</b> No: J. Goldman <b>15:40-16:00</b> Discussion				
16:00-16:30	<i>Coffee Break</i>							
16:30-18:00	<b>Session 4</b> <b>ACUTE LYMPHATIC LEUKEMIA (ALL)</b>  <b>16:30-17:15</b> Is the efficacy of the pediatric-like protocols for ALL superior to the protocols for adult ALL? <b>16:30-16:35</b> Moderator: R. Foà <b>16:35-16:45</b> Yes: J.P. Marie <b>16:45-16:55</b> No: J. Ribera <b>16:55-17:15</b> Discussion  <b>17:15-18:00</b> Should the induction for Ph+ ALL be based on TKI alone or TKI plus chemotherapy? <b>17:15-17:20</b> Moderator: J.P. Marie <b>17:20-17:30</b> TKI Alone: R. Foà <b>17:30-17:40</b> TKI plus chemotherapy: O. Ottmann <b>17:40-18:00</b> Discussion	<b>Session 7</b> <b>MULTIPLE MYELOMA (MM)</b>  <b>16:30-17:15</b> Multiple Myeloma in patients <70 years: Cure vs. disease control <b>16:30-16:35</b> Moderator: N. Kröger <b>16:35-16:45</b> Cure: J.F. San-Miguel <b>16:45-16:55</b> Control: M. Boccadoro <b>16:55-17:15</b> Discussion  <b>17:15-18:00</b> Should Therapy for newly diagnosed MM be risk adapted? <b>17:15-17:20</b> Moderator: M. Boccadoro <b>17:20-17:30</b> Yes: B. Barlogie <b>17:30-17:40</b> No: E. Terpos <b>17:40-18:00</b> Discussion	<b>Session 11</b> <b>Hodgkin and non-Hodgkin lymphoma</b>  <b>16:30-17:15</b> Has PET/CT an established role in the management of HD and NHLs? <b>16:30-16:35</b> Moderator: M. Björkholm <b>16:35-16:45</b> Yes: M. Hutchings <b>16:45-16:55</b> No: U. Vitolo <b>16:55-17:15</b> Discussion  <b>17:15-18:00</b> Does molecular outcome prediction in DLBCL add clinical value? <b>17:15-17:20</b> Moderator: M. Björkholm <b>17:20-17:30</b> Yes: C. Gisselbrecht <b>17:30-17:40</b> No: M. Pfreundschuh <b>17:40-18:00</b> Discussion	<b>Session 15</b> <b>HEMOGLOBINOPATHIES &amp; PNH</b> <b>16:30-18:30</b>  <b>16:30-16:50</b> Pros and cons of gene therapy in beta-thalassemia <b>16:30-16:35</b> Moderator: L. Luzzatto <b>16:35-16:50</b> Lecture: S. Rivella  <b>16:50-17:10</b> The controversies in the use of chelating drugs for the treatment of iron overload affect the morbidity and mortality of thalassemia and other transfused patients worldwide <b>16:50-16:55</b> Moderator: E. Rachmilewitz <b>16:55-17:10</b> Lecture: G. Kontoghiorghes  <b>17:10-17:50</b> How far one should go with iron chelation in thalassemia? Is iron deficiency indicated? <b>17:10-17:15</b> Moderator: E. Rachmilewitz <b>17:15-17:25</b> Yes: V. Berdoukas <b>17:25-17:35</b> No: M.D. Cappellini <b>17:35-17:50</b> Discussion  <b>17:50-18:30</b> Do the benefits of complement blockade extend to all patients with PNH clone? <b>17:50-17:55</b> Moderator: <b>17:55-18:05</b> Yes: J. Maciejewski <b>18:05-18:15</b> No: L. Luzzatto <b>18:15-18:30</b> Discussion				



The 1<sup>st</sup> World Congress on  
**Controversies in Hematology (COHEM)**  
 Rome, Italy  
 September 2-5, 2010